EP0735044B1 - Preparation of D4T from 5-methyluridine - Google Patents

Preparation of D4T from 5-methyluridine Download PDF

Info

Publication number
EP0735044B1
EP0735044B1 EP96301606A EP96301606A EP0735044B1 EP 0735044 B1 EP0735044 B1 EP 0735044B1 EP 96301606 A EP96301606 A EP 96301606A EP 96301606 A EP96301606 A EP 96301606A EP 0735044 B1 EP0735044 B1 EP 0735044B1
Authority
EP
European Patent Office
Prior art keywords
mixture
compound
bromo
afford
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96301606A
Other languages
German (de)
French (fr)
Other versions
EP0735044A1 (en
Inventor
Richard H. Spector
Bang-Chi Chen
Sandra L. Quinlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0735044A1 publication Critical patent/EP0735044A1/en
Application granted granted Critical
Publication of EP0735044B1 publication Critical patent/EP0735044B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Definitions

  • the compound d4T (2',3'-didehydro-3'-deoxythymidine) is a new antiviral drug approved recently for the treatment of AIDS. It is named Stavudine by the U.S. Adopted Name (USAN) and marketed as ZERIT.TM
  • the current process for producing d4T uses an expensive starting material, thymidine.
  • thymidine for a leading reference see: Joshi, B.V.; Rao, T.; Sudhakar, R.; Reese, C.B., J. Chem. Soc. Perkin Trans. I , 1992, 2537.
  • Alternative approaches to d4T utilize less costly ribonucleoside 5-methyluridine (5-MU).
  • the present invention is a new improved synthesis of d4T from 5-methyluridine ( 1 ) (Scheme 1).
  • the key step of this invention involves a metal reductive elimination of a mixture of novel trans -3' ⁇ -halo-2' ⁇ -acyloxy/ trans -3' ⁇ -acyloxy-2' ⁇ -halo derivatives of 5-MU 5a and 5b to give 5'-mesyl-d4T ( 6 ).
  • the present invention concerns an improved process of making d4T from 5-MU. Another aspect of the invention relates to useful intermediates produced during the process.
  • C refers to straight and branched chain alkyl groups with one to six carbon atoms, and such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl, or the like alkyl groups.
  • Aryl means aromatic hydrocarbon having six to ten carbon atoms; examples include phenyl and naphthyl which can optionally be substituted with one to five halogen atoms, C 1-6 alkyl and/or aryl groups.
  • Acyl refers to a radical RCO- in which R is C 1-6 alkyl.
  • Halogen means chlorine, bromine and iodine.
  • Alkali metal refers to metal in Group IA of the periodic table, preferably lithium, sodium and potassium.
  • Alkaline earth metal refers to metal in Group IIA of the periodic table, preferably calcium and magnesium.
  • each regioisomer can be isolated during these steps from a mixture of 4a and 4b , or 5a and 5b , and the following reactions can be carried on each separated regioisomer to eventually afford d4T.
  • NMR nuclear magnetic resonance
  • N-Methylmorpholine (29.6 mL, 266 mmoles) was added to a slurry of 5-methyluridine hemihydrate (15.64 g, 58.5 mmoles) in acetone (68 mL) and the resulting mixture was cooled to 5°C.
  • a solution of methanesulfonyl chloride (20.1 mL, 255 mmoles) in acetone (30 mL) was added over 45 minutes, causing the reaction temperature to rise to 45-50°C.
  • the N-methylmorpholine hydrochloride was removed by filtration and the cake was washed with acetone (2 x 30 mL).
  • the combined filtrate and washes were then added to water (1 L) at 10-15°C. After stirring for 1.1 hours the white precipitate was filtered, washed with water (2 x 75 mL), and dried under vacuum. Yield 27.95 g (97%).
  • Ratio of two isomers was 2.53:1.
  • 1 H-NMR data for the minor isomer (DMSO-d 6 ) ⁇ 1.79 (s, 3H), 1.96 (s, 3H), 3.22 (s, 3H), 4.4-4.7 (m, 5H), 6.18 (d, J 3.8 Hz, 1H), 7.59 (s, 1H), 11.48 (s, 1H).
  • n-butylamine 133 ml was added 5'-benzoyl-d4T ( 7' , 70.0 g). The reaction was heated at 70°C for six hours. After cooling to 20-25°C, N-methylpyrrolidinone (NMPO, 41.3 ml) and n-butyl acetate (350 ml) were added. Excess n-butylamine ( ⁇ 112.4 ml) along with 175 ml of n-butyl acetate was removed via vacuum distillation at 50°C. The resulting slurry was cooled to 20-25°C over one hour and stirred for 30 minutes. The slurry was then cooled to -10 to -15°C and stirred for 1.5 hours. The cake was filtered and washed with 2x50 ml cold (-10 to -15°C) n-butyl acetate and dried to give d4T ⁇ NMPO complex, 59.0 g (85.6%).

Abstract

The present invention concerns an improved process of making d4T from 5-MU. Another aspect of the invention relates to useful intermediates produced during the process.

Description

  • The compound d4T (2',3'-didehydro-3'-deoxythymidine) is a new antiviral drug approved recently for the treatment of AIDS. It is named Stavudine by the U.S. Adopted Name (USAN) and marketed as ZERIT.™ The current process for producing d4T uses an expensive starting material, thymidine. (For a leading reference see: Joshi, B.V.; Rao, T.; Sudhakar, R.; Reese, C.B., J. Chem. Soc. Perkin Trans. I, 1992, 2537.) Alternative approaches to d4T utilize less costly ribonucleoside 5-methyluridine (5-MU). (For reviews see: Huryn, D.M.; Okabe, M., Chem. Rev., 1992, 92, 1745; Dueholm, K.L.; Pedersen, E.B., Synthesis, 1992, 1; Herdewijin, P.; Balzarini, J.; De Clercq, E., in Advances in Antiviral Drug Design, Vol. 1, De Clercq, E., Ed., JAI Press Inc., Middlesex, England, 1993, p. 233.) For example, zinc reduction of cis-3'α-acetyloxy-2'α-bromo derivative of 5-MU affords d4T product in about 50% yield. (See Mansuri, M.M.; Starrett, J.E., Jr.; Wos, J.A.; Tortolani, D.R.; Brodfuehrer, P.R.; Howell, H.G.; Martin, J.C., J. Org. Chem., 1989, 54, 4780.) However, large amount of thymine by-product also forms via competitive elimination which requires expensive chromatographic separation from the d4T product. Alternative methods of making this antiviral agent are constantly explored in order to find a more economical method of preparing the large-scale amounts of d4T.
  • The present invention is a new improved synthesis of d4T from 5-methyluridine ( 1 ) (Scheme 1). The key step of this invention involves a metal reductive elimination of a mixture of novel trans-3'α-halo-2'β-acyloxy/trans-3'β-acyloxy-2'α-halo derivatives of 5-MU 5a and 5b to give 5'-mesyl-d4T ( 6 ). In sharp contrast to the previous zinc reduction of cis-3'α-acetyloxy-2'α-bromo derivative of 5-MU where about 40% of thymine by-product is formed (Mansuri, M.M.; Starrett, J.E., Jr.; Wos, J.A.; Tortolani, D.R.; Brodfuehrer, P.R.; Howell, H.G.; Martin, J.C. J. Org. Chem., 1989, 54, 4780), the zinc reduction of trans-acyloxy halo derivatives of 5-MU 5a and 5b in which X is bromo and R is methyl affords d4T without noticeable thymine by-product contamination.
  • The present invention concerns an improved process of making d4T from 5-MU. Another aspect of the invention relates to useful intermediates produced during the process.
  • In the instant application, unless otherwise specified explicitly or in context, the following definitions apply. The numbers in subscript after the symbol "C" define the number of carbon atoms a particular group can contain. For example "C1-6 alkyl" refers to straight and branched chain alkyl groups with one to six carbon atoms, and such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl, or the like alkyl groups. "Aryl" means aromatic hydrocarbon having six to ten carbon atoms; examples include phenyl and naphthyl which can optionally be substituted with one to five halogen atoms, C1-6 alkyl and/or aryl groups. "Acyl" refers to a radical RCO- in which R is C1-6 alkyl. "Halogen," "halide," or "halo" means chlorine, bromine and iodine. Alkali metal refers to metal in Group IA of the periodic table, preferably lithium, sodium and potassium. Alkaline earth metal refers to metal in Group IIA of the periodic table, preferably calcium and magnesium.
  • The abbreviations used herein are conventional abbreviations widely employed in the art; some of which are:
  • Ms :
    Methanesulfonyl
    DMF :
    N,N-dimethylformamide
  • The improved d4T process of this invention is depicted in Scheme 1 and involves the following chemical reactions:
  • Step (a): The production of 2',3',5'-tri-O-mesyl-5-methyluridine ( 2 ) from 5-MU is described in EP-A-0 653 436, which is herein incorporated by reference in its entirety. More specifically, this step involves preferably the use of a polar solvent, such as acetone, and about 3 to 5 equivalents of an organic base that is stronger than pyridine but weaker than triethylamine. Useful organic bases are those such as the picolines, the lutidines, and preferably N-methylmorpholine; in effect, bases with pK values between 5.5 and 8.0. The reaction proceeds at warm temperatures such as room temperature to about 65°C and is complete usually within about 0.5 to 2.0 hours. Typical reaction conditions appear in Example 1 that follow.
  • Step (b): Treatment of compound 2 with MOH results in the formulation of 5'-mesyl-2',3'-anhydro-5-methyluridine ( 3 ). MOH refers to an alkali metal hydroxide such as potassium hydroxide, sodium hydroxide, and lithium hydroxide. Preferred MOH is sodium hydroxide in about 1N concentration. (A somewhat similar procedure has been previously reported for the preparation of 5'-mesyl-2',3'-anhydrouridine, see: Codington, J.F.; Fecher, R.; Fox, J.J., J. Org. Chem., 1962, 27, 163.)
  • Steps (c) and (d): The epoxide 3 is then opened with hydrogen halide selected from hydrogen chloride, hydrogen bromide and hydrogen iodide to afford a mixture of regioisomers 4a and 4b. Preferred hydrogen halide is hydrogen bromide which can be generated in situ from acetyl bromide and methanol to afford a mixture of alchohols 4a and 4b in which X is bromo. A mixture of 4a and 4b is then treated with acyl halide to give a mixture of regioisomers 5a and 5b . In this second step, acetyl bromide is preferred which affords trans-bromoacetates.
  • If one so desires, each regioisomer can be isolated during these steps from a mixture of 4a and 4b, or 5a and 5b, and the following reactions can be carried on each separated regioisomer to eventually afford d4T.
  • Step (e): The reductive elimination of a mixture of 5a and 5b with a reducing metal, such as zinc, magnesium, zinc-couple such as Zn-Cu, or sodium affords 5'-mesyl-d4T ( 6 ). Here the preferred reducing metal is zinc. As stated earlier the advantage of this specific reductive elimination is that it proceeds cleanly in high yield with little or no cleavage of thymine which is difficult to separate from the product. (Compound 6 is described in Joshi, B.V.; Reese, C.B., J. Chem. Soc. Perkin Trans. I, 1992, 441.) (Zinc reduction of trans-acetyloxy bromo derivatives of adenosine (Ia and Ib) have been reported, see: Robins, M.J. et al, Tetrahedron Lett., 1984, 25, 367. However, not only the nucleo base is different from thymine, but the orientations of the acyloxy and halo groups are different from 5a and 5b, e.g. 3'β-bromo-2'α-acetyloxy/3'α-acetyloxy-2'β-bromo vs 3'α-bromo-2'β-acetyloxy/3'β-acetyloxy-2'α-bromo. It is worthwhile to note that when the nucleo base is thymine instead of adenine, analogous compounds to Ia and Ib can not be obtained due to the thymine base participation, see Mansuri, M.M.; Starrett, J.E., Jr.; Wos, J.A.; Tortolani, D.R.; Brodfuehrer, P.R.; Howell, H.G.; Martin, J.C. J. Org. Chem., 1989, 54, 4780.)
    Figure 00040001
  • Step (f): Reaction of compound 6 with 1.2 equivalent of R'COOT in a polar solvent such as DMF at an elevated temperature such as at about 100° C for about 6 hours affords 5'-acyloxy-d4T of formula 7. T is an alkali or alkaline earth metal such as sodium, potassium, lithium, calcium, magnesium, etc, and R' is C1-6 alkyl or aryl. Preferred R'COOT is sodium benzoate.
  • Step (g): The conversion of a compound of formula 7 to d4T can be achieved by many conventional methods known to convert esters to alcohols. Prior art syntheses of d4T generally use sodium methoxide in methanol to achieve the 5'-deprotection. EP-A-0 653 436,
  • teaches the clean deprotection of benzoyl (or another acyl group) with n-butylamine. Furthermore, the addition of N-methylpyrrolidinone (NMPO) in butyl acetate allows isolation of the d4T·NMPO complex by filtration from the reaction mixture. This isolation via the NMPO solvate effectively eliminates contaminants which are difficult to separate from product, particularly on a large scale. The d4T·NMPO complex can be decomposed by heating in isopropanol to give d4T in high yield and purity.
    Figure 00060001
    Figure 00070001
  • The specific examples that follow illustrate the instant invention, and are not to be construed as limiting the invention in sphere or scope. The methods may be adapted to variations in order to produce the compounds embraced by this invention, and without departing from the spirit of the invention. Further, variations of the methods to produce the same compounds in somewhat different manner will also be evident to one skilled in the art.
  • In the following experimental procedures, all temperatures are understood to be in Centigrade (C) when not specified. The nuclear magnetic resonance (NMR) spectral characteristics refer to chemical shifts (δ) expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the proton NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported as broad singlet (bs or br s), broad doublet (bd or br d), broad triplet (bt or br t), broad quartet (bq or br q), singlet (s), multiplet (m), doublet (d), quartet (q), triplet (t), doublet of doublet (dd), doublet of triplet (dt), and doublet of quartet (dq). The solvents employed for taking NMR spectra are acetone-d6 (deuterated acetone). DMSO-d6 (perdeuterodimethylsulfoxide), D2O (deuterated water), CDCl3 (deuterochloroform) and other conventional deuterated solvents.
  • EXAMPLE 1 2',3',5'-Tris(methanesulfonyl)-5-methyluridine (2) Pyridine procedure
  • To a stirred mixture of 5-methyluridine (12.8g, 50 mmol) in pyridine (75 ml) at 0°C was added methanesulfonyl chloride (17.4 ml, 225 mmol). The reaction mixture was stirred at 0°C for five hours then poured into ice-water (500 ml) with stirring.
    Tris(methanesulfonyl)-5-methyluridine 2 precipitated and the mixture was stirred for 5 min. The solid product was collected by filtration and washed with water (3x200 ml) and dried. Yield 21.6g, 89%.
    1H-NMR (DMSO-d6) δ 1.77 (s, 3H), 3.24 (s, 3H), 3.34 (s, 3H), 3.36 (s, 3H), 4.47-4.60 (m, 2H), 5.33 (m, 1H), 5.54 (m, 1H), 5.97 (d, J=4.5 Hz, 1H), 7.56 (s, 1H), 11.56 (s, 1H).
  • N-Methylmorpholine procedure
  • N-Methylmorpholine (29.6 mL, 266 mmoles) was added to a slurry of 5-methyluridine hemihydrate (15.64 g, 58.5 mmoles) in acetone (68 mL) and the resulting mixture was cooled to 5°C. A solution of methanesulfonyl chloride (20.1 mL, 255 mmoles) in acetone (30 mL) was added over 45 minutes, causing the reaction temperature to rise to 45-50°C. After stirring an additional 1.4 hours the N-methylmorpholine hydrochloride was removed by filtration and the cake was washed with acetone (2 x 30 mL). The combined filtrate and washes were then added to water (1 L) at 10-15°C. After stirring for 1.1 hours the white precipitate was filtered, washed with water (2 x 75 mL), and dried under vacuum. Yield 27.95 g (97%).
  • EXAMPLE 2 5'-Methanesulfonyl-2',3'-anhydro-5-methyluridine (3)
  • To a solution of 49 ml 1N sodium hydroxide was added 2',3',5'-tris(methanesulfonyl)-5-methyluridine ( 2 , 6.0g). The mixture was stirred at 70-72 °C for 15 minutes and then cooled 0°C. The pH was adjusted to 4 by using concentrated HCl. The resulting slurry was filtered, washed with 2x10 ml water and dried to give 5'-methanesulfonyl-2'-3'-anhydro-5-methyluridine (3), 3.1g, (84%).
    1H-NMR (DMSO-d6) δ 1.79 (s, 3H), 3.22 (s, 3H), 4.10 (m, 2H), 4.38 (m, 2H), 4.55 (m, 1H), 6.15 (s, 1H), 7.49 (s, 1H), 11.48 (s, 1H).
  • EXAMPLE 3 1β-(5'β-Methanesulfonyl-2'β-hydroxy-3'α-bromofuranosyl)-thymine and 1β-(5'β-Methanesulfonyl-2α-bromo-3'β-hydroxyfuranosyl)-thymine (4a' and 4b')
  • To a mixture of 5'-methanesulfonyl-2',3'-anhydro-5-methyluridine ( 3 , 2.4g) in 120 ml of methanol was added acetyl bromide (6.0 ml). The reaction mixture was then refluxed for 7 hours. The solvent was removed to give an oil which was dried under vaccum to give a mixture of compounds 4a' and 4b', 2.9g (96%).
  • Ratio of two isomers was 2.53:1. 1H-NMR data for the major isomer (DMSO-d6) δ 1.79 (s, 3H), 3.24 (s, 3H), 4.40-4.60 (m, 5H), 6.20 (d, J=6.6 Hz, 1H), 7.38 (s, 1H), 11.38 (s, 1H); 1H-NMR data for the minor isomer (DMSO-d6) δ 1.79 (s, 3H), 1.96 (s, 3H), 3.22 (s, 3H), 4.4-4.7 (m, 5H), 6.18 (d, J=3.8 Hz, 1H), 7.59 (s, 1H), 11.48 (s, 1H).
  • EXAMPLE 4 1β-(5'β -Methanesulfonyl-2'β-acetoxy-3'α-bromofuranosyl)-thymine and 1β-(5'β-Methanesulfonyl-2α-bromo-3'β-acetoxyfuranosyl)-thymine (5a' and 5b')
  • To a mixture of the hydroxy bromides 4a' and 4b' (1.2g) in 20 ml of ethyl acetate was added acetyl bromide (2.0 ml). The reaction was refluxed for 2 hours. After cooling, the reaction mixture was diluted with 40 ml of ethyl acetate, washed with saturated NaHCO3 (2x50 ml), brine (50 ml) and dried over MgSO4. Removal of solvent afforded a mixture of bromo acetates 5a' and 5b', 1.25g (95%).
    Ratio of two isomers was 2.6:1. 1H-NMR data for the major isomer (DMSO-d6) δ 1.79 (s, 3H), 1.94 (s, 3H); 3.25 (s, 3H), 4.40-4.70 (m, 4H), 5.62 (t, J=6.8 Hz, 1H), 6.35 (d, J=6.7 Hz, 1H), 7.40 (s, 1H), 11.42 (s, 1H); 1H-NMR data for the minor isomer (DMSO-d6) δ 1.79 (s, 3H), 1.96 (s, 3H), 3.24 (s, 3H), 4.40-4.70 (m, 4H), 5.57 (t, J=3.7 Hz, 1H), 6.35 (d, J=3.8 Hz, 1H), 7.49 (s, 1H), 11.48 (s, 1H).
  • EXAMPLE 5 5'-Methanesulfonyl-2',3'-didehydro-3'-deoxythymidine (6)
  • To a mixture of 1.0g of activated zinc dust in 25 ml methanol was added the bromo acetates 5a' and 5b' (1.0g). The mixture was stirred at room temperature for 1.5 hours. Excess zinc was filtered and washed with 2x10 ml methanol. Removal of solvent afforded 5'-mesyl-d4T ( 6 ), 0.60g (88%).
    1H-NMR (DMSO-d6) δ 1.73 (s, 3H), 3.16 (s, 3H), 4.40 (m, 2H), 5.02 (s, 1H), 6.03 (d, J=5.8 Hz, 1H), 6.42 (d, J=5.9 Hz, 1H), 6.84 (m, 1H), 7.27 (s, 1H), 11.39 (s, 1H).
  • EXAMPLE 6 5'-Benzoyl-2'3'-didehydro-3'-deoxythymidine (7')
  • To a mixture of 5'-mesyl-d4T ( 6 , 0.4g) in 6 ml of DMF was added powdered sodium benzoate (0.24g). The reaction was stirred at 100 °C for 6 hours. After cooling, water (30 ml) was added. The resulting precipitate was filtered, washed with 2x5 ml water and dried to give 5'-benzoly-d4T ( 7' ), 0.04g (91%).
    1H-NMR (DMSO-d6) δ 1.35 (s, 3H), 4.41-4.48 (m, 2H), 5.10 (m, 1H), 6.04 (d, J=5.8 Hz, 1H), 6.53 (d, J=5.8 Hz, 1H), 6.80 (s, 1H), 7.10 (s, 1H), 7.51-7.95 (m, 5H), 11.37 (s, 1H).
  • EXAMPLE 7 2',3'-Didehydro-3'-deoxythymidine-N-methylpyrrolidinone complex
  • To n-butylamine (133 ml) was added 5'-benzoyl-d4T ( 7' , 70.0 g). The reaction was heated at 70°C for six hours. After cooling to 20-25°C, N-methylpyrrolidinone (NMPO, 41.3 ml) and n-butyl acetate (350 ml) were added. Excess n-butylamine (∼112.4 ml) along with 175 ml of n-butyl acetate was removed via vacuum distillation at 50°C. The resulting slurry was cooled to 20-25°C over one hour and stirred for 30 minutes. The slurry was then cooled to -10 to -15°C and stirred for 1.5 hours. The cake was filtered and washed with 2x50 ml cold (-10 to -15°C) n-butyl acetate and dried to give d4T·NMPO complex, 59.0 g (85.6%).
  • EXAMPLE 8 2',3'-Didehydro-3'-deoxythymidine (d4T) Methoxide procedure
  • To a stirred slurry of 5'-benzoyl-d4T ( 7' ) (2.4 g, 7.31 mmol) in methanol (24 ml) was added sodium methoxide solution (4.8 mL, 25%, 21 mmol). The resulting solution was stirred at room temperature for 3 hours. The reaction mixture was neutralized with strong acid resin (Dowex 50x8-200, prewashed with methanol) to pH 4. The resin was filtered and the cake was washed with methanol (2x10ml). Removal of methanol gave a wet solid to which methylene chloride (10 ml) was added. The resulting mixture was stirred for 30 min. and then the d4T product was collected by filtration, washed with methylene chloride (2x5ml) and dried. Yield 1.29 g, 79%.
    1H-NMR (DMSO-d6) δ 1.71 (s, 3H), 3.59 (m, 1H), 4.76 (m, 1H), 5.02 (s, 1H), 5.89 (d, J=5.7 Hz, 1H), 6.38 (d, J=5.7 Hz, 1H), 6.80 (s, 1H), 7.63 (s, 1H), 11.27 (s, 1H).
  • d4T·NMPO complex procedure
  • To 500 ml of isopropanol was added 50.0 g d4T·NMPO, 5.0 g Dicalite, 5.0 g Darco KB. The mixture was heated to reflux and then filtered hot through a bed of Dicalite. The filter cake was rinsed with 150 ml hot isopropanol. The filtrate and rinse were combined and vacuum concentrated to a final volume of 200 ml. The concentrated mixture was heated to reflux to give a solution and then cooled slowly to form product slurry at 50°C. The slurry was then cooled to 0°C and held for 30 minutes. The cake was filtered, washed with cold (0°C) isopropanol and dried to give d4T , 30.5 g (87.9%).

Claims (14)

  1. A process of producing 2',3'-didehydro-3'-deoxythymidine (d4T) comprising the steps of:
    a) treating 2',3',5'-tris(methanesulfonyl)-5-methyluridine ( 2 )
    Figure 00140001
    with alkali metal hydroxide to afford epoxide 3
    Figure 00140002
    b) treating epoxide 3 with hydrogen halide to afford a mixture of compounds 4a and 4b in which X is chloro, bromo or iodo
    Figure 00150001
    c) treating a mixture of 4a and 4b with acyl halide to afford a mixture of 5a and 5b in which R is C1-6 alkyl
    Figure 00150002
    d) treating a mixture of 5a and 5b with reducing metal to afford compound 6
    Figure 00150003
    (e) reacting compound 6 with R'COOT, in which T is alkali or alkaline earth metal selected from sodium, potassium, lithium, calcium or magnesium; and R' is aryl or C1-6 alkyl; to afford a compound of formula 7
    Figure 00160001
    and
    (f) converting R'COO- radical in a compound of formula 7 to hydroxy.
  2. The process of claim 1 in which alkali metal hydroxide of step (a) is sodium hydroxide.
  3. The process of claim 1 or 2 in which hydrogen halide of step (b) is hydrogen bromide.
  4. The process of claim 1, 2 or 3 in which acyl halide of step (c) is acetyl bromide.
  5. The process of claim 1, 2, 3 or 4 in which reducing metal of step (d) is zinc.
  6. A process of producing 2',3'-didehydro-3'-deoxythymidine (d4T) including the steps of reacting a compound of 5a or 5b, or a mixture thereof
    Figure 00170001
    in which X is chloro, bromo or iodo; and R is C1-6 alkyl; with a metal reducing agent to afford compound of formula
    Figure 00170002
    6
  7. The process as claimed in claim 6 in which R is methyl, X is bromo, and metal reducing agent is zinc.
  8. The compound of formula 3
    Figure 00180001
  9. A compound of formula 4a or 4b, or a mixture thereof
    Figure 00180002
    in which X is chloro, bromo or iodo.
  10. A compound or a mixture of claim 9 in which X is bromo.
  11. A compound of formula 5a or 5b, or a mixture thereof.
    Figure 00190001
    in which X is chloro, bromo or iodo; and R is C1-6 alkyl.
  12. A compound or a mixture of claim 11 in which X is bromo, and R is methyl.
  13. The process of any one of claims 1 to 5 in which the conversion of step (f) is effected by using C1-6 alkylamine.
  14. The process of claim 13 in which alkali metal hydroxide of step (a) is sodium hydroxide; hydrogen halide of step (b) is hydrogen bromide; acyl halide of step (c) is acetyl bromide; reducing metal of step (d) is zinc; R'COOT of step (e) is sodium benzoate; and C1-6 alkylamine of step (f) is n-butylamine.
EP96301606A 1995-03-10 1996-03-08 Preparation of D4T from 5-methyluridine Expired - Lifetime EP0735044B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/402,283 US5608049A (en) 1995-03-10 1995-03-10 Preparation of d4T from 5-methyluridine
US402283 1995-03-10

Publications (2)

Publication Number Publication Date
EP0735044A1 EP0735044A1 (en) 1996-10-02
EP0735044B1 true EP0735044B1 (en) 1999-06-23

Family

ID=23591286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96301606A Expired - Lifetime EP0735044B1 (en) 1995-03-10 1996-03-08 Preparation of D4T from 5-methyluridine

Country Status (18)

Country Link
US (1) US5608049A (en)
EP (1) EP0735044B1 (en)
JP (1) JP3914279B2 (en)
KR (1) KR100393913B1 (en)
CN (2) CN1059213C (en)
AT (1) ATE181556T1 (en)
AU (1) AU694320B2 (en)
CA (1) CA2170968A1 (en)
CY (1) CY2155B1 (en)
DE (1) DE69602983T2 (en)
DK (1) DK0735044T3 (en)
ES (1) ES2135168T3 (en)
GR (1) GR3031243T3 (en)
HK (1) HK1002979A1 (en)
HU (1) HU220700B1 (en)
IL (1) IL117225A (en)
SG (1) SG38948A1 (en)
TW (1) TW527359B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608048A (en) * 1995-06-05 1997-03-04 Bristol-Myers Squibb Company d4 T polymorphic Form 1 process
WO2002020538A2 (en) * 2000-09-06 2002-03-14 Bristol-Myers Squibb Company Stavudine polymorphic form 1 process
AU2004275770A1 (en) * 2003-09-22 2005-04-07 Acidophil Llc Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20050131224A1 (en) * 2003-12-15 2005-06-16 Cti Pet Systems, Inc. Method for preparing radiolabeled thymidine
US7160537B2 (en) * 2003-12-15 2007-01-09 Siemens Medical Solutions Usa, Inc. Method for preparing radiolabeled thymidine having low chromophoric byproducts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
US4904770A (en) * 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
JP3128080B2 (en) * 1991-10-02 2001-01-29 日本製紙株式会社 Novel method for producing nucleic acid compounds
US5672698A (en) * 1993-11-15 1997-09-30 Bristol-Myers Squibb Co. Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine
US5539099A (en) * 1993-11-15 1996-07-23 Bristol-Myers Squibb Company Process for large-scale preparation of 2',3'-didehydro-2',3'-dideoxynucleosides

Also Published As

Publication number Publication date
ATE181556T1 (en) 1999-07-15
HK1002979A1 (en) 1998-09-30
DK0735044T3 (en) 2000-01-10
DE69602983T2 (en) 2000-03-09
EP0735044A1 (en) 1996-10-02
CY2155B1 (en) 2002-08-23
CN1059213C (en) 2000-12-06
JP3914279B2 (en) 2007-05-16
CN1147519A (en) 1997-04-16
ES2135168T3 (en) 1999-10-16
AU4798296A (en) 1996-09-19
DE69602983D1 (en) 1999-07-29
AU694320B2 (en) 1998-07-16
IL117225A (en) 2001-04-30
KR960034212A (en) 1996-10-22
CA2170968A1 (en) 1996-09-11
HUP9600607A1 (en) 1996-12-30
CN1195770C (en) 2005-04-06
SG38948A1 (en) 1997-04-17
TW527359B (en) 2003-04-11
HU220700B1 (en) 2002-04-29
GR3031243T3 (en) 1999-12-31
US5608049A (en) 1997-03-04
JPH08269051A (en) 1996-10-15
CN1270172A (en) 2000-10-18
KR100393913B1 (en) 2003-12-18
IL117225A0 (en) 1996-06-18

Similar Documents

Publication Publication Date Title
US5672698A (en) Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine
EP0638586B1 (en) Nucleoside derivatives and methods for producing them
EP0735044B1 (en) Preparation of D4T from 5-methyluridine
JPH051092A (en) Nucleoside derivative and its production
EP0653437B1 (en) Process for preparing AZT and derivatives thereof
KR100699099B1 (en) 1-?-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof
JPWO2005070946A1 (en) Solution phase synthesis of ribonucleic acid compounds and oligonucleic acid compounds
JPH0217199A (en) Production of 2'-deoxy-beta-adenosine
JP2666160B2 (en) 5-O-pyrimidyl-2,3-dideoxy-1-thiofuranoside derivative, method for producing the same and use
CA2552583A1 (en) Improved synthesis of 2-substituted adenosines
JPH06135988A (en) Nucleotide derivative
JP4174895B2 (en) Nucleoside derivatives and their production
JPH06135989A (en) Nucleotide derivative
JP2014506593A (en) Synthesis of FLG

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19970305

17Q First examination report despatched

Effective date: 19970606

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 181556

Country of ref document: AT

Date of ref document: 19990715

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69602983

Country of ref document: DE

Date of ref document: 19990729

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

ITF It: translation for a ep patent filed

Owner name: MODIANO & ASSOCIATI S.R.L.

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2135168

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19990908

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20061212

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070301

Year of fee payment: 12

Ref country code: CH

Payment date: 20070301

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20070304

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20070307

Year of fee payment: 12

Ref country code: GB

Payment date: 20070307

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20070308

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20070313

Year of fee payment: 12

Ref country code: IE

Payment date: 20070313

Year of fee payment: 12

Ref country code: AT

Payment date: 20070313

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20070314

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20070315

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20070417

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20070514

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20070525

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20070214

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070308

Year of fee payment: 12

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20080908

BERE Be: lapsed

Owner name: *BRISTOL-MYERS SQUIBB CY

Effective date: 20080331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080308

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080908

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080308

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081001

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20081001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20081125

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080309

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080310

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081001

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20080310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081002

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080308